Is HALO or HCWB more undervalued in 2026?

CirclFi compares Halozyme Therapeutics, Inc. (HALO) and HCW Biologics Inc. (HCWB) using 13 institutional-grade valuation models. HALO has a Quality of Company score of 10.0/10 while HCWB scores 3.9/10.

Which is a better buy — HALO or HCWB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HALO and HCWB valuations compare?

HALO at $68.18 and HCWB at $2.09 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HALO vs HCWB Valuation Comparison 2026 — Intrinsic Value Analysis

HALO

Biotechnology

Halozyme Therapeutics, Inc.

Quality

10.0

out of 10

Value Trap

LOW

Price

$68.18

Last close

Models

12/13

Active

HCWB

Biotechnology

HCW Biologics Inc.

Quality

3.9

out of 10

Value Trap

LOW

Price

$2.09

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	HALO Fair Value	HALO Upside	HCWB Fair Value	HCWB Upside
Bayesian DCF	Intrinsic	$75.34	+10.5%	—	—
Earnings Power Value	Intrinsic	$23.07	-66.2%	$0.29	-35.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	—	—	$0.35	-83.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HALO vs HCWB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HALO vs HCWB — Which Stock Is More Undervalued?

HALO scores higher with a 10.0/10 quality rating vs HCWB's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Halozyme Therapeutics, Inc. (HALO) and HCW Biologics Inc. (HCWB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HALO currently trades at $68.18 with a QOC of 10.0/10, while HCWB trades at $2.09 with a QOC of 3.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).